Navigation Links
New FDA regulations puts some cough syrups off market

The Food and Drug Administration's(FDA) new effort to re-examine very old drugs that began selling before the government ever required proof that drugs worked well, has landed dozens of brands of prescription cough syrup in trouble. Until now FDA stressed that the expectorant, extended-release guaifenesin, is not dangerous. However, the recent crackdown lead to the FDA formally approving sale of Adams// Laboratories' Mucinex, making competing companies' unapproved versions automatically illegal. The FDA has warned 66 manufacturers that Mucinex would be the only once-a-day prescription guaifenesin allowed to sell unless its competitors won formal approval. The FDA has given these companies time till end of November to pull their brands of extended-release guaifenesin off the market.


'"/>




Page: 1

Related medicine news :

1. Avenues to opened for medical tourists following relaxation of visa regulations
2. Hostility breeds against Homeopathy in England following new regulations
3. Negligent doctors asked to cough up 3 lakhs for death of patient
4. Iron supplements proves helpful in dry cough .
5. Hypertensive drugs may cause cough
6. Sensitive cough suffered by females
7. How to arrest cough
8. Chronic cough can lead to depression
9. High Incidence of Whooping cough
10. Australia coughs up $15m to resurrect Lebanon
11. Indias anti-AIDS drug market engaged in price war
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New FDA regulations puts some cough syrups off market

(Date:7/25/2014)... CA (PRWEB) July 25, 2014 DON’T PAUSE ... help alleviate uncomfortable bloating, hot flashes, mood swings, burning ... identified by Dr. Shoreh Ershadi. The AntiAging Institute of California ... Menopause that allows women to try this revolutionary product. For ... PAUSE can get a third bottle at no charge. ...
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... Researchers at the University of Bordeaux in Bordeaux, France have ... man-made material used in high-heat insulation may increase the risk ... has just posted an article on the new study. ... French scientists studied the work histories of 988 men ... group of workers had been exposed to asbestos only while ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... for the Guinness International Champions Cup Match between Manchester ... Bronx, New York, one of the most iconic locations is ... original Yankee Stadium, but it is quickly becoming a location ... The facility is home to the New York Yankees from ...
(Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 2Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2
... , NASHVILLE, Tenn. and GLEN ROCK, N.J., ... 76 percent of surveyed pharmacy directors say that by ... only one preferred biologic for all immune conditions, such ... According to the new Formulary Forum report entitled ...
... , , , ... GHDX ) today announced that Kim Popovits, Genomic Health,s Chief ... Growth Conference in Boston, on Thursday, August 13 at 1:30 p.m. ... subsequently archived webcast of the presentation, visit the Investor Relations section ...
... , , HOUSTON, Aug. 6 ... a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated ... trial is being conducted under a Bellicum Investigational New Drug application ... results of the study in 2010. , , ...
... , , KIBBUTZ SHAMIR, ... SHMR ) (" Shamir ") expects to issue its second quarter ... a conference call to discuss the results at 11:00 A.M. EDT that ... broadcast live as a listen-only webcast. To listen live, please go to ...
... , , NEW YORK, ... synthetic peptide technology shown to significantly help improve the appearance of ... now available through select physicians to help their patients achieve picture ... can be found in leading physician offices for $120 per 1 ...
... , SALT LAKE CITY, Aug. 6 ... silicon nitride ceramic technologies, announced today that Ben Shappley has joined ... Shappley will also serve on the company,s Board of Directors. , ... of orthopaedic and neurosurgical implant experience in both management and senior ...
Cached Medicine News:Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:Ben Shappley Joins Amedica's Leadership Team 2
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of Tokyo ... next-generation sequencing (NGS) gene panels, for blood cancers  ... new test, indicate favorable prognosis for patients with bone ... sees potential for developing companion diagnostics to guide treatment ...
(Date:7/24/2014)... Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased by ... Reported sales increased 5% which included a 1% benefit ... as reported (EPS) were $2.49, compared with $2.24 in ... an increase of 9% over the prior-year amount of ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... a differential medium designed for the ... Selective agents are incorporated for the ... of S. epidermidis and yeast. S. ... in mauve colonies, thus permitting differentiation ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
... a 180 watt Xenon short arc lamp. Designed to ... the lamp to the light guide, this light source ... higher watt bulbs. A new IR filtering system and ... amount of heat generated from the light source and ...
... standardize your video equipment has led Linvatec ... couplers to accommodate all of your multi-specialty ... "V mount couplers in both traditional eyecup ... also offer a 20-42mm Zoom "C mount ...
Medicine Products: